Stable neurological function in subjects treated with 2'3'-dideoxyinosine.
AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'-dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.
Sidtis
J J
JJ
Department of Neurology, University of Minnesota, Minneapolis, USA.
Dafni
U
U
Slasor
P
P
Hall
C
C
Price
R W
RW
Kieburtz
K
K
Tucker
T
T
Clifford
D B
DB
D015526:AIDS Dementia Complex / Q000503:physiopathology / Q000517:prevention & control*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D016049:Didanosine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D009483:Neuropsychological Tests; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015215:Zidovudine; D016049:Didanosine